Seasonal Variability of Severe Asthma Exacerbations and Clinical Benefit from Lebrikizumab

Post-hoc analyses of two Phase III studies of lebrikizumab in moderate to severe asthma suggest that IL-13 inhibition is effective at preventing seasonal exacerbations in subjects with high blood eosinophil counts. Further work is required to understand and treat exacerbations that are independent of seasonal and Type 2 pathway factors.

http://ift.tt/2lx5Afp